Immunohistochemistry (IHC) to assess tumor cell-associated OX40 expression in lymphoma PDXs （Poster #: 1027, April，7）
Hanx Bio 15th Annual T-Cell Lymphoma Forum poster_HX009 vs OX40_Henry_Tao edits
Hanx Bio 15th Annual T-Cell Lymphoma Forum poster_HX129_Henry edits
Narazaciclib, a novel multi-kinase inhibitor, with potent activity against CSF1R, FLT3 1 and CDK6, shows strong anti-AML activity in defined preclinical models
Genomic profiling of leukemic cell lines, responders vs. non-responders to Narazaciclib (HX301 or ON123300), a novel kinase inhibitor with activity against CSF1R and FLT3 （Poster #: 2262, April，8）
Preclinical pharmacology modeling (pharmacokinetics/efficacy) of narazaciclib (HX301 or ON123300) to predict its clinical effective dose （Poster #: 7161，April，10th
2023年演示材料
Discovery of HX011, a novel OX40 mAb, for potential cancer immunotherapy (#6346, April 19th)
Non-clinical pharmacology of HX009, a novel FIC PD1xCD47 BsAb (#6345, April 19th)
T-cell activation enhanced by PD1 blockade and CD47 cis-blockade of PD1xCD47 BsAb HX009 (#543, Nov. 3rd)
Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy (#502, Nov. 4th)
HX301, a First-in-class ARK5i, Demonstrates Antitumor Activity in Preclinical HCC Models with High ARK5/Myc Expression
HX301 (ON1232580), a novel kinase inhibitor with potent activity against CSF1R and FLT3, shows strong anti-AML activity in defined preclinical models (#5665, April 18th)
2022年演示材料
A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinom
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter,single-arm, open-label, phase Ib trial
Safety and efficacy of Pucotenlimab (HX008) - a Humanized Immunoglobulin G4 Monoclonal Antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
HX009, a clinical stage first-in-class PD-1xCD47 BsAb, shows strong antitumor activity in preclinical lymphoma models
ASCO 2021:First in Human Phase I Dose Escalation Study of HX009, a Novel Recombinant Humanized Anti CD47/PD 1 Bispecific Antibody, in Patients with Advanced Malignancies
